Search results
Results from the WOW.Com Content Network
Agovirin Depot: Aqueous suspension: 50–100 mg 1x/1–2 weeks Testosterone phenylacetate b: Perandren, Androject: Oil solution: 50–200 mg 1×/3–5 weeks Mixed testosterone esters: Sustanon 100, Sustanon 250: Oil solution: 50–250 mg 1×/2–4 weeks Testosterone undecanoate: Aveed, Nebido: Oil solution: 750–1,000 mg 1×/10–14 weeks ...
Lupron injection was approved by the FDA for treatment of advanced prostate cancer on 9 April 1985. [45] [4] [43] [44] Lupron depot for monthly intramuscular injection was approved by the FDA for palliative treatment of advanced prostate cancer on 26 January 1989. [8]
A depot injection, also known as a long-acting injectable (LAI), is a term for an injection formulation of a medication which releases slowly over time to permit less frequent administration of a medication.
They are provided as an oil solution and are administered by intramuscular injection. [5] The different testosterone esters provide for different elimination half-lives in the body. Esterification of testosterone provides for a sustained but non-linear release of testosterone hormone from the injection depot into the circulation. Sustanon 100 ...
Another type of puberty blocker includes progestins, such as medroxyprogesterone acetate, which can be taken orally or by injection and work by reducing the body's production of sex hormones. In some cases, aromatase inhibitors are used off-label to block the conversion of androgens into estrogens, although they are less commonly prescribed.
Medications and dosages used in transgender women [1] [2] [3] [4] [5] [a]; Medication Brand name Type Route Dosage [b]; Estradiol: Various: Estrogen: Oral: 2–10 mg ...
Depot MPA (DMPA) and EC/MPA were developed by Upjohn in the 1960s. [12] [13] DMPA (brand name Depo-Provera) was introduced for use as a progestogen-only injectable contraceptive for the first time outside of the United States in 1969 and was subsequently approved for use in birth control in the United States in 1992.
Estrogen levels after a single intramuscular injection of 10 mg estradiol valerate in oil in 24 postmenopausal women. [9] Determinations were made for both Progynon Depot 10 and Estradiol Depot 10, for a total of 48 measurements per point. [9] Assays were performed using GC/MS-NCI/SIM. [9] Source was Schug et al. (2012). [9]